Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis

Author： Gowin Krisstina   Mesa Ruben  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.12, 2013-12, pp. : 1603-1611

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Molecular Pathogenesis of Philadelphia Chromosome Negative Chronic Myeloproliferative Neoplasms

By  

Current Cancer Drug Targets, Vol. 11, Iss. 1, 2011-01 ,pp. : 20-30

Bentham Science Publishers

Access to resources Recommend Favorite

Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives

By  

Current Drug Targets, Vol. 12, Iss. 3, 2011-01 ,pp. : 392-419

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging and future therapies for the treatment of bone loss associated with chronic inflammation

By Haynes D.  

Inflammopharmacology, Vol. 14, Iss. 5-6, 2006-12 ,pp. : 193-197

Springer Publishing Company

Access to resources Recommend Favorite

Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia

By Fullmer Amber   Kantarjian Hagop   Cortes Jorge   Jabbour Elias  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 3065-3072

Informa Healthcare

Access to resources Recommend Favorite

Nilotinib: In the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase

By Garnock-Jones Karly P.  

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1579-1590

Adis International

Access to resources Recommend Favorite